Abstract

In the last years, different kinds of limbic encephalitis associated with autoantibodies against ion channels and synaptic receptors have been described. Many studies have demonstrated that such autoantibodies induce channel or receptor dysfunction. The same mechanism is discussed in immune-mediated cerebellar ataxias (IMCAs), but the pathogenesis has been less investigated. The aim of the present review is to evaluate what kind of cerebellar ion channels, their related proteins, and the synaptic machinery proteins that are preferably impaired by autoantibodies so as to develop cerebellar ataxias (CAs). The cerebellum predictively coordinates motor and cognitive functions through a continuous update of an internal model. These controls are relayed by cerebellum-specific functions such as precise neuronal discharges with potassium channels, synaptic plasticity through calcium signaling pathways coupled with voltage-gated calcium channels (VGCC) and metabotropic glutamate receptors 1 (mGluR1), a synaptic organization with glutamate receptor delta (GluRδ), and output signal formation through chained GABAergic neurons. Consistently, the association of CAs with anti-potassium channel-related proteins, anti-VGCC, anti-mGluR1, and GluRδ, and anti-glutamate decarboxylase 65 antibodies is observed in IMCAs. Despite ample distributions of AMPA and GABA receptors, however, CAs are rare in conditions with autoantibodies against these receptors. Notably, when the autoantibodies impair synaptic transmission, the autoimmune targets are commonly classified into three categories: release machinery proteins, synaptic adhesion molecules, and receptors. This physiopathological categorization impacts on both our understanding of the pathophysiology and clinical prognosis.

Highlights

  • Autoantibodies of ion channels and receptors can elicit neurological symptoms [1]

  • The aim of the present review is to evaluate what kind of cerebellar ion channels, their related proteins, and the synaptic machinery proteins that are preferably impaired by autoantibodies so as to develop cerebellar ataxias (CAs)

  • Recent studies have documented the association of CAs with autoantibodies toward leucine-rich glioma-inactivated 1 (LGI1), contactin-associated protein-like 2 (Caspr2), dipeptidyl-peptidase-like protein-6 (DPPX), AMPA, GluRδ, GABA, and glycine-receptors, the data regarding clinical specificities and pathophysiological profiles are scarce due to the rare prevalence of these conditions

Read more

Summary

Introduction

Autoantibodies of ion channels and receptors can elicit neurological symptoms [1]. In the past two decades, there has been accumulating physiological and clinical evidence showing that autoantibodies against potassium channel-associated proteins, glutamate receptors, and GABA receptors impair neural excitability or synaptic transmission, resulting in limbic encephalitis [2,3,4,5]. The aim of the present review is to evaluate what kind of cerebellar ion channels, their related proteins, and the synaptic machinery proteins that are preferably impaired by autoantibodies so as to develop cerebellar ataxias (CAs). The cerebellar targets of autoantibodies are classified physiologically into two categories of ion channels and synaptic transmission-related proteins. The latter could be further classified into: 1. We argue that the categorization of synaptic targets could be related to clinical prognosis

Overview of Cerebellar Physiology—Ion Channels and Synaptic Machinery
Neuronal Network in the Cerebellum
Presynaptic and Inter-Synaptic Machinery
Synaptic Adhesion Molecules
Receptors at the Post-Synaptic Membrane of Purkinje Cells
Receptor Trafficking at PF-PC Synapse
Overview
Clinical Profile of Anti-VGCC Ab-Associated CA
Effects of Autoantibodies
Clinical Profile of Anti-mGluR1 Ab-Associated CA
Clinical Profile of Anti-GAD65 Ab-Associated CA
Clinical Profile of Anti-DPPX Ab-Associated CA
Clinical Profile of Anti-Caspr2 Ab-Associated CA
Clinical Profile of Anti-GluRδ Ab-Associated CA
Clinical Profile of Anti-AMPAR Ab-Associated CA
Clinical Profile of Anti-Glycine Ab-Associated CA
3.10.1. Clinical Profile of Anti-GABAAR Ab-Associated CA
3.10.2. Effects of Autoantibodies
3.11.1. Clinical Profile of Anti-GABAB R Ab-Associated CA
3.11.2. Effects of Autoantibodies
3.12.1. Clinical Profile of Anti-LGI1 Ab-Associated CA
3.12.2. Effects of Autoantibodies
3.13. Other Autoantibodies Lacking Characterization
Region-Specific Vulnerability to Autoantibodies
Physiological Categorization of Autoantibodies
Receptors
Findings
Conclusions
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call